Albireo Dashes Into PFIC Market As FDA, EMA Approve Bylvay

The company anticipates an addressable global market for progressive familial intrahepatic cholestasis of 2,500 patients, with initial plans to focus on around 100 physicians at 60 centers.

liver
Albireo is aiming to launch Bylvay immediately in the US, targeting around 100 physicians at 60 centers • Source: Shutterstock

Albireo Pharma Inc. anticipates a rapid launch of Bylvay (odevixibat) after it received back-to-back approvals from the US Food and Drug Administration and European Medicines Agency for progressive familial intrahepatic cholestasis (PFIC), with reimbursement expected to come through over the course of the second half of the year in the US and Europe.

The Boston-based company said 20 July that it received FDA approval for Bylvay for pruritis in all subtypes of PFIC,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Rare Diseases

More from Scrip